The DOI matches its Crossref record.
134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Sorted by citations
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationWu, S., & Shih, J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0777-1 · Cited by 796
“2% del19/L858R) Semi-quantitative The only FDA approved ctDNA assay for detection of EGFR mutations [70, 71]”
Burstein, H. J., Krilov, L., Aragon‐Ching, J. B., Baxter, N. N., Chiorean, E. G., Chow, W. A., Groot, J. F. D., Devine, S. M., DuBois, S. G., El‐Deiry, W. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5292 · Cited by 603
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Self-citationImpact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U. G., Fidock, M. D., Hamrén, B., Johnson, A. G., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 470
Precision Oncology: Who, How, What, When, and When Not?
Schwartzberg, L. S., Kim, E. S., Liu, D., & Schrag, D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174176 · Cited by 294
Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
Sacher, A. G., Komatsubara, K. M., & Oxnard, G. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.022 · Cited by 102
“6%).(23) This discordance is hypothesized to be related to the heterogeneity of drug resistance.”
BackgroundThe Importance of Biopsy in the Era of Molecular Medicine
Ziv, E., Durack, J. C., & Solomon, S. B. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000228 · Cited by 80
“In 1 study, there was high concordance between T790Mpositive plasma and T790M tissue biopsies, and in a second study, there was high correlation between T790M-positive plasma and response rates to T790M-targeting EGFR inhibitor.(63,64) However, unstable molecules such as RNA and protein are less likely to be reliably…”
BackgroundThe emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
Zhang, Y.-C., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0536-6 · Cited by 60
Juan, Ó., & Popat, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687262 · Cited by 43
“ORR to osimertinib was similar in ctDNA T790M-positive patients and tissue positive patients (64% and 66%, respectively) [Jenkins et al. 2016].”
ResultTargeting the EGFR T790M mutation in non-small-cell lung cancer
Normanno, N., Maiello, M. R., Chicchinelli, N., Iannaccone, A., Esposito, C., Cecio, R. D., D’Alessio, A., & Luca, A. D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1272582 · Cited by 37
Kim, E. J.-H., Feldman, R. A., & Wistuba, I. I. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.08.001 · Cited by 23
Spiegel, M. L., Goldman, J. W., Wolf, B. R., Nameth, D. J., Grogan, T., Lisberg, A. E., Wong, D. J. L., Ledezma, B. A., Mendenhall, M. A., Genshaft, S. J., et al. (2017) · Cancer · doi:10.1002/cncr.31056 · Cited by 22
Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
Melosky, B. L. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00038 · Cited by 17
Santos, E. S., Kaplan, B. H., Kirshner, E., Croft, E. F., Sequist, L. V. D., Chau, M., Munley, J. Y., & Oxnard, G. R. (2018) · Oncology and Therapy · doi:10.1007/s40487-018-0061-y · Cited by 8
Melosky, B. L., Popat, S., & Gandara, D. R. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.019 · Cited by 8
The Introduction and Clinical Application of Cell-Free Tumor DNA
Li, J., Liu, R., Huang, C., Chen, S., & Xu, M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7717-8_4 · Cited by 4
Ogawara, D., Soda, H., Suyama, T., Yoshida, M., Harada, T., Fukuda, Y., & Mukae, H. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12538 · Cited by 1
Mehta, M. P. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727072323.793552491
Kelly, R. J., Turner, R., Chen, Y., Rigas, J. R., Fernandes, A. W., & Karve, S. J. (2018) · doi:10.2196/preprints.11858
Metadata
- Authors
- Jenkins, S., Yang, J., Ramalingam, S., Yu, K., Patel, S., Weston, S., Lawrance, R., Cantarini, M., Jänne, P., & Mitsudomi, T.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- National Taiwan University Hospital (TW)
- Emory University (US)
- Kindai University (JP)
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 11
- Issue
- 4
- Pages
- S153-S154
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2340752593
- Cited by
- 20
- References
- 0
- Citations by year
- 2021: 1 · 2018: 6 · 2017: 10 · 2016: 3
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- T790M mutation, liquid biopsy, circulating tumor DNA, plasma ctDNA, osimertinib, EGFR-mutant non-small cell lung cancer, EGFR tyrosine kinase inhibitor resistance, cobas EGFR Mutation Test, test agreement, L858R mutation, exon 19 deletion, biopsy avoidance, treatment response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
